Lundbeck upgrades annual earnings guidance, cuts revenue outlook
Revenue will end up in the lower end of the spread Lundbeck forecast in early 2021, the Danish pharmaceutical firm informs after closing the first two quarters of this year.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
After making it through the first half of 2021, Lundbeck adjusts its annual financial guidance, which was set rather wide in the beginning of the year. Now the group makes both upward and downward adjustments.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck closes RNA deal worth USD 109m with US biotech firm
For subscribers
Lundbeck to trial migraine drug in young people
For subscribers
.jpg&w=384&q=75)
